One hundred ninety-three Streptococcus agalactiae isolates of neonatal origin and 146 isolates from adult women were analyzed for macrolide resistance and investigated for clonality. Among erythromycin-resistant isolates, serotype V turned out to be the most frequent. Comparative pulsed-field gel electrophoresis analysis revealed genetic clustering of resistant strains and predominance of a single clone family within an otherwise heterogeneous serotype V population. [GBS]) is the leading cause of meningitis and early-onset sepsis in neonates (3,21). Penicillin or ampicillin is the drug of choice for prophylaxis and treatment of GBS disease (1, 5). However, erythromycin and clindamycin are the recommended second-line drugs and the first alternative in case of a -lactam allergy. In recent years, increasing macrolide resistance rates have been reported (9,15,16,17,19). Resistance mechanisms include target site modification mediated by erm genes leading to resistance to macrolides-lincosamides-streptogramin B (MLS phenotype) with either inducible or constitutive expression or an efflux mechanism encoded by mef genes mediating resistance only to 14-and 15-membered macrolides (M phenotype). After the first description of serotype V in 1977 (26), several studies reported a major increase of serotype V GBS among clinical isolates in the early 1990s (8,13). To analyze the recent increase in macrolide resistance among GBS isolates in our region, the present study aimed to explore the issue of a clonal spread of resistant strains by means of randomly amplified polymorphic DNA (RAPD) analysis and restriction digest patterns (RDP) derived from pulsed-field gel electrophoresis (PFGE). Moreover, a possible correlation between the increase of a certain serotype and macrolide resistance was explored. Streptococcus agalactiae (group B StreptococcusThe bacterial strains used in this study have been presented previously (20). In brief, of 193 neonatal GBS strains, 26 invasive isolates were cultured from blood or cerebrospinal fluid while 167 isolates were grown from urine samples and swab cultures. A total of 146 GBS isolates from vaginal swabs of pregnant women were randomly collected. Serotyping was performed by using an enzymatic extraction method (2). All erythromycin-resistant isolates were screened by PCR analysis for erythromycin resistance genes (mefA or mefE, ermB, and ermTR) by using primers previously described (7,23,24). PCR assays were reproducibly repeated at least three times for every strain. Differentiation of specific MLS phenotypes was performed by use of a triple-disk test (10). For RAPD analysis, the core sequence of phage M13 and the previously described primer OPS16 were used (6, 12) and visual inspection of bands served to compare RAPD patterns for similarity. Different isolates with the same migration distances of all visible bands were considered highly similar. The presence or absence of two distinct bands was deemed to indicate a difference. Chromosomal DNA of GBS strains was prepared by modifications o...
There is still a low rate of penicillin/ampicillin resistance in S. pneumoniae, and H. influenzae, but an alarming increase in resistance to erythromycin, and in H. influenzae a significant increase in cefaclor resistance was observed over the 10-year period in South-Western Germany.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.